Skip to content

Q10 co-enzyme effect on fetus implantation

Q10 co-enzyme effect on fetus implantation in ART cycles in infertile persons

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015102724746N1
Enrollment
128
Registered
2015-12-13
Start date
2015-03-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility. Female infertility

Interventions

Intervention 1: In this study,intervention group will be prescribed the drug Q10 to implantation of the embryo after administration of the study. Intervention 2: The control group will be given medici
Treatment - Drugs
In this study,intervention group will be prescribed the drug Q10 to implantation of the embryo after administration of the study.
The control group will be given medicines to evaluate the implantation of the embryo in the intervention group.

Sponsors

Women's Reproductive Health Research Center,Vice chancellor for research, Tabriz University of Medic
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 42 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria; women with ages between 20 and 42 years who have a high number of embryos transferred are fresh.(The maximum number of embryos transferred in the order of 2 to 3 cycles of ovulation induction (Fresh Embryo)). Exclusion criteria; associated with individual factors such as women over 42 years; the number of embryos down; diseases such as patients with gastrointestinal disorders; patients with liver disorders; gynecological factors like endometriosis; genital anomalies such as disorders of the fallopian tube; uterine anatomic abnormalities.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Embryo Quality. Timepoint: monthly after drug Prescription. Method of measurement: evaluation of pregnancy with B-HCG test at the end of drug use.;Embryo. Timepoint: monthly after drug Prescription. Method of measurement: evaluation of pregnancy with B-HCG test at the end of drug use.;Ovule. Timepoint: monthly after drug Prescription. Method of measurement: evaluation of pregnancy with B-HCG test at the end of drug use.

Secondary

MeasureTime frame
Pregnancy ratio. Timepoint: monthly. Method of measurement: pregnancy lab test (B-HCG).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Samira Abdollahi

Tabriz University Of Medical Sciences

abdollahis@tbzmed.ac.ir+98 41 3330 8229

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026